<DOC>
	<DOCNO>NCT02568241</DOCNO>
	<brief_summary>This study aim evaluate efficacy interferon α prophylactic donor lymphocyte infusion ( DLI ) among high-risk acute leukemia patient undergone unmanipulated blood marrow transplantation . Hematopoietic stem cell transplantation ( HSCT ) effective treatment option high-risk acute leukemia ( AL ) . However , post-transplant relapse occur patient , prognosis patient usually poor.Prophylactic DLI decrease risk relapse high-risk AL patient . Interferon α-2b exerts relatively strong immunomodulatory effect . It kill AL cell regulate T-cell and/or natural killer cell functions.Consequently , interferon α-2b may potential value high-risk AL patient transplantation . The study hypothesis : Using interferon α-2b prophylactic DLI follow hematopoietic stem cell transplantation patient high-risk AL reduce relapse rate improve leukemia-free survival .</brief_summary>
	<brief_title>Interferon-α After DLI Prevention Relapse</brief_title>
	<detailed_description>High risk acute leukemia patient ( except ( 9 ; 22 ) ( q34 ; q11 ) cytogenetic abnormality . ) receive interferon α-2b prophylactic DLI day 30-60 unmanipulated blood marrow transplantation . The end point safety , leukemia-free survival , immunologic response . Following time 12 month .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients highrisk acute leukemia hematopoietic stem cell transplantation Patients ( 9 ; 22 ) ( q34 ; q11 ) cytogenetic abnormality ; active graftversushost disease ; active infection ; organ failure , relapse</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Relapse</keyword>
	<keyword>Donor lymphocyte infusion</keyword>
</DOC>